Thermo Fisher Scientific Inc (NYSE:TMO) CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Thermo Fisher Scientific Inc (NYSE TMO) traded down $0.44 during trading on Friday, hitting $190.17. 1,145,983 shares of the stock were exchanged, compared to its average volume of 1,545,246. Thermo Fisher Scientific Inc has a fifty-two week low of $139.07 and a fifty-two week high of $201.20. The stock has a market capitalization of $76,030.00, a price-to-earnings ratio of 20.78, a price-to-earnings-growth ratio of 1.73 and a beta of 1.08. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. During the same quarter in the prior year, the firm earned $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s payout ratio is 10.19%.

TRADEMARK VIOLATION NOTICE: “Thermo Fisher Scientific Inc (TMO) CEO Marc N. Casper Sells 50,000 Shares of Stock” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://theolympiareport.com/2017/11/18/thermo-fisher-scientific-inc-tmo-ceo-marc-n-casper-sells-50000-shares-of-stock.html.

Several institutional investors have recently added to or reduced their stakes in the company. Covington Capital Management grew its holdings in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock worth $374,000 after buying an additional 20 shares in the last quarter. Investment Centers of America Inc. grew its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 21 shares during the period. Fort Washington Investment Advisors Inc. OH grew its holdings in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 23 shares during the period. Azimuth Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 25 shares during the period. Finally, Bienville Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after purchasing an additional 27 shares during the period. 83.78% of the stock is owned by institutional investors and hedge funds.

Several research firms recently issued reports on TMO. Jefferies Group LLC reiterated a “hold” rating and issued a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $197.00 price objective for the company in a research report on Tuesday, August 1st. BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. The Goldman Sachs Group, Inc. began coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective for the company. Finally, Barclays PLC restated an “overweight” rating and set a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $205.71.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.